434 related articles for article (PubMed ID: 10954886)
1. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
Wiznia A; Stanley K; Krogstad P; Johnson G; Lee S; McNamara J; Moye J; Jackson JB; Mendez H; Aguayo R; Dieudonne A; Kovacs A; Bamji M; Abrams E; Rana S; Sever J; Nachman S
AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1113-21. PubMed ID: 10954886
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
[TBL] [Abstract][Full Text] [Related]
4. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.
Smith D; Hales G; Roth N; Law M; Ray J; Druett J; Mitchell J; Mills G; Doong N; Franklin R;
HIV Clin Trials; 2001; 2(2):97-107. PubMed ID: 11590517
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
11. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
13. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
Fletcher CV; Yogev R; Nachman SA; Wiznia A; Pelton S; McIntosh K; Stanley K
Pharmacotherapy; 2004 Apr; 24(4):453-9. PubMed ID: 15098798
[TBL] [Abstract][Full Text] [Related]
15. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
Plana M; Ferrer E; Martínez C; Podzamczer D; García F; Maleno MJ; Barceló JJ; García A; Barberá MJ; Lacarcel M; Miró JM; Gallart T; Gatell JM
Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
[TBL] [Abstract][Full Text] [Related]
16. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
Nadal D; Steiner F; Cheseaux JJ; Lazarevitch CA; Aebi C; Kind C; Rudin C
Infection; 2000 Sep; 28(5):287-96. PubMed ID: 11073135
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
18. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
20. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Skowron G
Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]